

Sameh M. Hakim, M.D., Ain Shams University, Cairo, Egypt. drsmichel@hotmail.com

References

1. Hakim SM, Othman AI, Naoum DO: Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: A randomized trial. *ANESTHESIOLOGY* 2012; 116:987–97
2. Ceriana P, Fanfulla F, Mazzacane F, Santoro C, Nava S: Delirium in patients admitted to a step-down unit: Analysis of incidence and risk factors. *J Crit Care* 2010; 25: 136–43
3. Cole M, McCusker J, Dendukuri N, Han L: The prognostic significance of subsyndromal delirium in elderly medical inpatients. *J Am Geriatr Soc* 2003; 51:754–60
4. Ouimet S, Riker R, Bergeon N, Cossette M, Kavanagh B, Skrobik Y: Subsyndromal delirium in the ICU: Evidence for a disease spectrum. *Intensive Care Med* 2007; 33: 1007–13
5. Kalisvaart KJ, de Jonghe JF, Bogaards MJ, Vreeswijk R, Egberts TC, Burger BJ, Eikelenboom P, van Gool WA: Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: A randomized placebo-controlled study. *J Am Geriatr Soc* 2005; 53:1658–66
6. Prakanrattana U, Prapaitrakool S: Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. *Anaesth Intensive Care* 2007; 35:714–9
7. Bojar RM: *Manual of Perioperative Care in Adult Cardiac Surgery*, 4th edition. Malden: Blackwell Publishing Inc.; 2005:235–63
8. Inouye SK, Bogardus ST Jr., Charpentier PA, Leo-Summers L, Acampora D, Holford TR, Cooney LM Jr: A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med* 1999; 340:669–76
9. Inouye SK, Bogardus ST Jr., Baker DI, Leo-Summers L, Cooney LM Jr: The Hospital Elder Life Program: A model of care to prevent cognitive and functional decline in older hospitalized patients. *Hospital Elder Life Program. J Am Geriatr Soc* 2000; 48:1697–706
10. Siddiqi N, Holt R, Britton AM, Holmes J: Interventions for preventing delirium in hospitalised patients. *Cochrane Database Syst Rev* 2007; CD005563
11. Marcantonio ER, Flacker JM, Wright RJ, Resnick NM: Reducing delirium after hip fracture: A randomized trial. *J Am Geriatr Soc* 2001; 49:516–22
12. The Delirium Clinical Guidelines Expert Working Group and the Delirium Consultancy Steering Committee: Clinical practice guidelines for the management of delirium in older people. Melbourne: The Victorian Government Department of Human Services; 2006:45–50
13. Cole MG, McCusker J, Bellavance F, Primeau FJ, Bailey RF, Bonnycastle MJ, Laplante J: Systematic detection and multidisciplinary care of delirium in older medical inpatients: A randomized trial. *CMAJ* 2002; 167:753–9
14. Inouye SK, Bogardus ST Jr., Williams CS, Leo-Summers L, Agostini JV: The role of adherence on the effectiveness of nonpharmacologic interventions: Evidence from the delirium prevention trial. *Arch Intern Med* 2003; 163:958–64
15. Young LJ, George J: Do guidelines improve the process and outcomes of care in delirium? *Age Ageing* 2003; 32: 525–8
16. Agostini JV, Baker DI, Inouye SK, Bogardus ST Jr: Multidisciplinary geriatric consultation services: Making health care safer: A critical analysis of patient safety practices. Rockville: AHRQ Publication; 2001:313–21

(Accepted for publication August 14, 2012.)

Hemorrhagic Shock and Acute Kidney Injury Model

To the Editor:

We have read with interest the review by Yap *et al.*¹ on acute kidney injury and extra renal organ dysfunction. We agree with their comments on the limitations of previously described models based on nephrotoxicants to explore acute kidney injury in animals. Surprisingly the authors wrote that “severe and prolonged hypotension in rats does not typically induce renal injury and is therefore not suitable for use as a “single insult” animal model.” Indeed, in a recent experimental study in mice, we have shown that a 2-hr pressure control hemorrhagic shock in mice induces prolonged decrease in glomerular filtration rate, histological lesions, and molecular hypoxic impact.² Moreover, 3 weeks after injury, sparse renal fibrosis and persistent tubular function abnormalities are present. In many respects and despite the limits of such anthropomorphism, this single-insult model reproduces closely both functional and histologic features of human ischemic acute kidney injury. This work and others sustain the potential interest of such a model.³

Nicolas Mayeur M.D.,* Vincent Minville M.D., Ph.D., Ivan Tack M.D., Ph.D.* Université Paul Sabatier, Toulouse, France. nicolas.mayeur@inserm.fr

References

1. Yap SC, Lee HT: Acute kidney injury and extrarenal organ dysfunction: New concepts and experimental evidence. *ANESTHESIOLOGY* 2012; 116:1139–48
2. Mayeur N, Minville V, Jaafar A, Allard J, Al Saati T, Guilbeau-Frugier C, Fourcade O, Girolami JP, Schaak S, Tack I: Morphologic and functional renal impact of acute kidney injury after prolonged hemorrhagic shock in mice. *Crit Care Med* 2011; 39:2131–8
3. van Meurs M, Kurniati NF, Wulfert FM, Asgeirsdottir SA, de Graaf IA, Satchell SC, Mathieson PW, Jongman RM, Kümpers P, Zijlstra JG, Heeringa P, Molema G: Shock-induced stress induces loss of microvascular endothelial Tie2 in the kidney which is not associated with reduced glomerular filtration function. *Am J Physiol Renal Physiol* 2009; 297:F272–81

(Accepted for publication August 15, 2012.)

In Reply:

We thank Mayeur *et al.* for their interest in our review on acute kidney injury and extra renal organ dysfunction.¹ As stated in our review, “single-insult” kidney injury models including complete renal ischemia, nephrotoxins, nephrectomy, or renal hypoperfusion do not completely recapitulate the multifactorial causes of clinical acute kidney injury. Single-insult models of kidney injury, however, have been invaluable in demonstrating the effects of acute kidney injury-mediated remote and multiorgan dysfunction.² We agree with Mayeur *et al.* that the hemorrhage and resuscitation model is used to produce multiorgan injury as well

as systemic inflammatory response syndrome.^{3,4} However, we disagree that it is a single-insult model of organ injury. The hemorrhage and resuscitation method is actually a “two-insult model” of multiorgan injury, as this model requires a period of controlled hemorrhage followed by resuscitation with shed blood. Resuscitation with shed blood exacerbates as well as causes multiorgan injury by promoting systemic inflammatory response, platelet activation, increased neutrophil recruitment and microthrombi formation.⁴

Steven C. Yap, M.D., H. Thomas Lee, M.D., Ph.D.*
*College of Physicians and Surgeons of Columbia University, New York, New York. tl128@columbia.edu

References

1. Yap SC, Lee HT: Acute kidney injury and extrarenal organ dysfunction: New concepts and experimental evidence. *ANESTHESIOLOGY* 2012; 116:1139–48
2. Park SW, Chen SW, Kim M, Brown KM, Kolls JK, D'Agati VD, Lee HT: Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy. *Lab Invest* 2011; 91:63–84
3. Mayeur N, Minville V, Jaafar A, Allard J, Al Saati T, Guilbeau-Frugier C, Fourcade O, Girolami JP, Schaak S, Tack I: Morphologic and functional renal impact of acute kidney injury after prolonged hemorrhagic shock in mice. *Crit Care Med* 2011; 39:2131–8
4. Harr JN, Moore EE, Wohlaer MV, Fragoso M, Gamboni F, Liang X, Banerjee A, Silliman CC: Activated platelets in heparinized shed blood: The “second hit” of acute lung injury in trauma/hemorrhagic shock models. *Shock* 2011; 36:595–603

(Accepted for publication August 15, 2012.)

Physostigmine and Restless Legs Syndrome

To the Editor:

Restless legs syndrome (RLS) is a common neurologic disorder that uncommonly manifests in the perioperative period. Its anesthetic implications were recently discussed,^{1,2} but the reviewers did not reference a 2005 case report that described rapid relief of symptoms with physostigmine.³ Their perioperative recommendations for prevention and treatment were based on the current theory of causation involving dysfunctional central iron and dopamine metabolism and six case reports in which no patient experienced prompt resolution of symptoms. Oral administration of the dopamine D2/D3 receptor agonist, 0.125 mg pramipexole, produced relief after 30 min.⁴ We report the second case of prompt relief of RLS symptoms with intravenous physostigmine.

A 65-yr-old man presented for endoscopic ultrasound and fine needle aspiration of a submucosal gastric lesion. The patient met the international standard essential criteria for RLS: irresistible urge to move his legs, accompanied

by unpleasant sensory complaints in his legs; increased agitation when the nursing staff insisted that he remain still; symptoms at home relieved by walking; and symptoms that are worse in the evening but reasonably controlled with dopamine D2/D3 receptor agonist therapy.^{1,5} His daily dose of pramipexole, extended-release 1.5 mg after dinner, was twice the maximum daily dose usually recommended for RLS⁶ and may reflect the severity of the syndrome. However, it is less than the average dose used to treat early Parkinson disease.⁷ His other comorbidities (medications) included obesity, obstructive sleep apnea, diabetes mellitus type 2 (insulin, metformin, glipizide), hypertension (lisinopril), coronary artery disease (aspirin, lovastatin), gastroesophageal reflux (omeprazole), and osteoarthritis (oxaprozin).

Anesthesia was provided with 2 mg midazolam, 440 mg propofol, and 10 mg ketamine intravenously (IV). He also received 4 mg ondansetron, 0.2 mg glycopyrrolate, and 20 mg IV esmolol and oxymetazoline intranasally before insertion of a nasopharyngeal airway. He was conversant on arrival in the recovery room. Within minutes he became agitated and tried to get off his stretcher to walk. He exhibited severe restlessness in both legs and complained of lower extremity tingling and tugging. The differential diagnoses in this setting included hypoxia (SpO₂ 98%), hypoglycemia (blood glucose 168 mg/dL), emergence delirium (conversant, oriented), neuroleptic-induced akathisia (no droperidol given), peripheral neuropathy, and a RLS flare (patient stated, “It’s my restless legs”). Administration of 1 mg IV physostigmine attenuated these symptoms within 3 min. Symptoms completely resolved with a second dose of 1 mg physostigmine. Five hours later, he was free of symptoms, despite not yet taking his usual evening dose of pramipexole.

It is difficult to reconcile this apparent effectiveness of physostigmine with the current view of the pathophysiology of RLS – central iron insufficiency altering the dopaminergic system with a decrease in the number of D2 receptors in the putamen, increased activity of tyrosine hydroxylase, and increased dopamine transporter density in the caudate, putamen, and striatum.^{1,8,9} But the cholinergic and dopaminergic systems do interact in certain brain regions, *e.g.*, striatal cholinergic output is dopamine D2 receptor-mediated.¹⁰

In summary, two patients with acute manifestations of RLS syndrome obtained prompt sustained relief after administration of physostigmine. A clinical trial in the nonperioperative setting is needed to confirm this beneficial effect. A positive outcome could spur a different line of research into the mechanisms involved.

Jeff Peacock, M.D., Girish Mishra, M.D., Raymond C. Roy, M.D., Ph.D.* *Wake Forest School of Medicine, Winston-Salem, North Carolina. rroy@wakehealth.edu

References

1. Raux M, Karroum EG, Arnulf I: Case scenario: Anesthetic implications of restless legs syndrome. *ANESTHESIOLOGY* 2010; 112:1511–7